SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 1

Otoimmün hepatitli bir hastada kadavradan karaciğer nakli sonrasında gelişen mide kanseri: olgu sunumu ve literatür derlemesi

Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: a case report and review of the literature

Çağatay ARSLAN
Saadettin KILIÇALP
Şuayib YALÇIN
Pages
73–76
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient did not receive any adjuvant therapy, and is free of disease at 9 months’ follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The risk of malignancy in transplant patients is higher than in the general population.
📊
Key Findings & Data:The risk is increased mostly due to immune alteration and viral infections.
💡
Conclusion & Impact:The patient did not receive any adjuvant therapy, and is free of disease at 9 months’ follow-up.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The risk of malignancy in transplant patients is higher than in the general population. The risk is increased mostly due to immune alteration and viral infections. While the most common cancers following liver transplantation include skin cancers, lymphoma and Kaposi’s sarcoma, gastric cancer is uncommon. Herein, we report a case of gastric adenocarcinoma developing three years after cadaveric liver transplantation in a patient with autoimmune hepatitis. The patient was successfully operated. The patient did not receive any adjuvant therapy, and is free of disease at 9 months’ follow-up.

Özet

Transplant hastalarında kanser genel popülasyona göre daha sık görülmektedir. Risk daha çok immün değişiklikler ve viral enfeksiyonlar ile artmaktadır. Karaciğer transplantasyonu sonrasında en sık cilt kanserleri, lenfoma ve kaposi sarkomu görülürken mide kanseri nadirdir. Bu yazıda otoimmün hepatitli bir hastada karaciğer transplantasyonundan 3 yıl sonra gelişen mide adenokarsinomunu rapor ettik. Hastaya başarılı bir cerrahi uygulandıktan sonra herhangi bir adjuvan tedavi verilmedi ve postoperatif dönemde 9. ayda hastalıksız olarak izlenmektedir.

🔖

Cite This Article

ARSLAN, Ç., KILIÇALP, S., YALÇIN, Ş. (2011). Otoimmün hepatitli bir hastada kadavradan karaciğer nakli sonrasında gelişen mide kanseri: olgu sunumu ve literatür derlemesi. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 1, 73–76. https://ajindex.com/articles/410826

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254-64
  2. Haberal M, Karakayali H, Emiroglu R, et al. Malignant tumors after renal transplantation. Artif Organs 2002; 26: 778-81
  3. Karakayali H, Haberal M. The history and activities of transplantation in Turkey. Transplant Proc 2005; 37: 2905-8
  4. Imao T, Ichimaru N, Takahara S, et al. Risk factors for malignancy in Japanese renal transplant recipients. Cancer 2007; 109: 2109-15
  5. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91
  6. Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-200
  7. Mithoefer AB, Supran S, Freeman RB, et al. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8: 939-44
  8. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol 2006; 44: 27-32
  9. Xiol X, Guardiola J, Menendez S, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001; 7: 971-5
  10. Sarkio S, Rautelin H, Kyllönen L, et al. Should Helicobacter pylori infection be treated before kidney transplantation? Nephrol Dial Transplant 2001; 16: 2053-7
  11. Spadaro M, Forni G. Proinflammatory cytokines, immune response and tumour progression. Novartis Found Symp 2004; 256: 92-9
  12. Spadaro M, Lanzardo S, Curcio C, Forni G, Cavallo F. Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 2004; 53: 204-16
  13. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapyrelated cancer. Nat Rev Cancer 2008; 8: 24-36
  14. Nagata Y, Eguchi S, Takatsuki M, et al. Experience of gastric cancer in a patient who had received a living-donor liver transplantation. Gastric Cancer 2007; 10: 187-90
  15. Baccarani U, Adani GL, Montanaro D, et al. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc 2006; 38: 1135-7
  16. Aberg F, Pukkala E, Höckerstedt K, et al. Risk of malignant neoplasms after liver transplantation: a populationbased study. Liver Transpl 2008; 14: 1428-36
  17. Herrero JI, Lorenzo M, Quiroga J, et al. De novo neoplasia after liver transplantation: an